EX-10.6(B) 12 a2221630zex-10_6b.htm EX-10.6(B)

Exhibit 10.6(b)

 

NEVRO CORP.

 

AMENDMENT TO
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 

This Amendment to Amended and Restated Registration Rights Agreement (this “Amendment”), by and among Nevro Corp., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company is made and entered into as of March 5, 2013, with respect to that certain Amended and Restated Registration Rights Agreement, dated as of February 8, 2013, by and among the Company and each of the stockholders of the Company listed on Exhibit A thereto, as such Exhibit A may be amended from time to time (the “Stockholders”) (the “Original Agreement”).  Capitalized terms used in this Amendment and not otherwise defined shall have the meaning ascribed to them in the Original Agreement.

 

RECITALS

 

WHEREAS, the Company and the Stockholders are parties to that certain Series C Convertible Preferred Stock Purchase Agreement, dated as of February 8, 2013, as amended by that certain Amendment to Series C Convertible Preferred Stock Purchase Agreement, dated as of even date herewith (together as amended, the “Purchase Agreement”), pursuant to which two new investors are purchasing shares of the Company’s Series C Preferred Stock (the “Series C Preferred Stock”) and Novo is purchasing additional shares of Series C Preferred Stock in a Subsequent Closing (as defined in the Purchase Agreement).

 

WHEREAS, in connection with the Subsequent Closing, the Company and the undersigned Stockholders desire to amend the Original Agreement in certain respects as set forth herein.

 

WHEREAS, pursuant to Section 14.3 of the Original Agreement, the provisions of the Original Agreement may be amended or waived at any time by the written agreement of the Company and Stockholders holding at least 70% of the Registrable Securities.

 

WHEREAS, any amendment or waiver effected in accordance with Section 14.3 of the Original Agreement shall be binding upon each holder of Registrable Securities and the Company.

 

WHEREAS, the undersigned Stockholders hold, in the aggregate, not less than 70% of the Registrable Securities, voting together as a single class on an as-converted basis.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the recitals and the mutual premises, covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 



 

1.                                      Amendments.

 

(A).                            Section 14.3 of the Original Agreement is hereby amended to add the following sentence: “Notwithstanding anything herein to the contrary, if pursuant to the Series C Stock Purchase Agreement, additional parties may purchase shares of Series C Preferred Stock in a Subsequent Closing (as defined in the Series C Stock Purchase Agreement) thereunder, then each such Purchaser (as defined in the Series C Stock Purchase Agreement) shall become a party to this Agreement as a “Stockholder” hereunder, without the need for any consent, approval or signature of any Stockholder when such Purchaser has both: (a) purchased shares of Series C Preferred Stock under the Series C Stock Purchase Agreement and paid the Company all consideration payable for such shares and (b) executed one or more counterpart signature pages to this Agreement.”

 

(B).                            Exhibit A to the Original Agreement is hereby amended in its entirety in the form attached as Exhibit A hereto.

 

2.                                      Reference to and Effect on the Original Agreement.  On or after the date hereof, each reference in the Original Agreement to “this Agreement,” “hereunder,” “herein” or words of like import shall mean and be a reference to the Original Agreement as amended hereby.  No reference to this Amendment need be made in any instrument or document at any time referring to the Original Agreement, a reference to the Agreement, in any of such to be deemed a reference to the Original Agreement as amended hereby.

 

3.                                      No Other Amendments.  Except as set forth herein, the Original Agreement shall remain in full force and effect in accordance with its terms.

 

4.                                      Counterparts.  This Amendment may be executed in any number of counterparts, each of which may be executed by less than all of the parties necessary to give effect to this Amendment, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument.

 

5.                                      Headings.  All section headings herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provisions of this Amendment or the Original Agreement.

 

6.                                      Governing Law.  This Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

 

(Signature Pages Follow)

 

2



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

NEVRO CORP.

 

 

 

 

 

By:

/s/ Michael DeMane

 

 

Name: Michael DeMane

 

 

Title:   Chief Executive Officer

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

NOVO A/S

 

 

 

 

 

By:

/s/ Kim Dueholm

 

 

Name: Kim Dueholm

 

 

Title:   Partner

 

 

 

 

 

Address:

Tuborg Havnevej 19

 

 

DK 2900 Hellerup

 

 

Denmark

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

JOHNSON & JOHNSON DEVELOPMENT CORPORATION

 

 

 

 

 

By:

/s/ Brad Vale

 

 

Name: Brad Vale

 

 

Title:   Vice President

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 


 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

BAY CITY CAPITAL FUND IV, L.P.

 

 

 

By:

Bay City Capital Management IV LLC

 

Its:

General Partner

 

 

 

 

By:

Bay City Capital LLC

 

Its:

Manager

 

 

 

 

 

 

By:

/s/ Fred Craves

 

 

 

Name:

Fred Craves

 

 

 

Title:

Authorized Signatory

 

 

 

 

 

BAY CITY CAPITAL FUND IV CO-INVESTMENT FUND, L.P.

 

 

 

By:

Bay City Capital Management IV LLC

 

Its:

General Partner

 

 

 

 

By:

Bay City Capital LLC

 

Its:

Manager

 

 

 

 

 

 

By:

/s/ Fred Craves

 

 

 

Name:

Fred Craves

 

 

 

Title:

Authorized Signatory

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

ABERDARE VENTURES III, LP

 

 

 

By:

Aberdare GP III, LLC

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ John H. Odden

 

 

 

Name:

John H. Odden

 

 

 

Title:  

Manager

 

 

 

 

 

ABERDARE PARTNERS III, LP

 

 

 

By:

Aberdare GP III, LLC

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ John H. Odden

 

 

 

Name:

John H. Odden

 

 

 

Title:  

Manager

 

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

THREE ARCH PARTNERS IV, L.P.

 

 

 

By:

Three Arch Management IV, L.L.C.

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ Wilfred Jaeger

 

 

 

Name:

Wilfred Jaeger

 

 

 

Title:

Managing Member

 

 

 

 

 

THREE ARCH ASSOCIATES IV, L.P

 

 

 

By:

Three Arch Management IV, L.L.C.

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ Wilfred Jaeger

 

 

 

Name:

Wilfred Jaeger

 

 

 

Title:  

Managing Member

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

MPM BIOVENTURES IV-QP, L.P.

 

 

 

By:

MPM BioVentures IV GP LLC

 

Its:

General Partner

 

 

 

By:

MPM BioVentures IV LLC

 

Its:

Managing Member

 

 

 

 

 

By:

/s/ James P. Scopa

 

Name:

James P. Scopa

 

Title:

Member

 

 

 

 

 

MPM BIOVENTURES IV GMBH & CO. BETEILIGUNGS KG

 

 

 

By:

MPM BioVentures IV GP LLC

 

Its:

Managing Limited Partner

 

 

 

By:

MPM BioVentures IV LLC

 

Its:

Managing Member

 

 

 

 

 

By:

/s/ James P. Scopa

 

Name:

James P. Scopa

 

Title:

Member

 

 

 

 

 

MPM ASSET MANAGEMENT INVESTORS BV4 LLC

 

By:

MPM BioVentures IV LLC

 

Its:

Manager

 

 

 

 

 

By:

/s/ James P. Scopa

 

Name:

James P. Scopa

 

Title:

Member

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

AMV PARTNERS II, L.P.

 

 

 

By:

Accuitive Medical Ventures II, LLC

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ Charles Larsen

 

 

 

Name:

Charles Larsen

 

 

 

Title:

Managing Director

 

SIGNATURE PAGE TO NEVRO CORP.

AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

 


 

EXHIBIT A

 

STOCKHOLDERS

 

Name/Address:

 

No. of Shares
of
Common
Stock

 

No. of Shares of
Series A
Preferred Stock

 

No. of Shares of
Series B
Preferred Stock

 

No. of Shares of
Series C
Preferred Stock

 

Novo A/S

 

 

 

 

47,516,198

 

 

 

 

 

 

 

 

 

 

 

Johnson & Johnson Development Corporation

Attn: Brad Vale
6500 Paseo Padre Dr.
Fremont, CA 94555

With a Copy to:
Attn: Jayne Zall
Assistant General Counsel
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

 

 

 

66,964,285

 

5,923,871

 

 

 

 

 

 

 

 

 

 

 

Bay City Capital Fund IV, L.P.

Attention: Carl Goldfischer
750 Battery Street
Suite 400
San Francisco, CA 94111

 

562,868

 

30,548,195

 

16,387,835

 

4,591,539

 

 

 

 

 

 

 

 

 

 

 

Bay City Capital Fund IV Co-Investment Fund, L.P.

Attention: Carl Goldfischer
750 Battery Street
Suite 400
San Francisco, CA 94111

 

12,132

 

658,461

 

353,236

 

98,970

 

 

 

 

 

 

 

 

 

 

 

Three Arch Partners IV, L.P.

Attention: Bill Harrington
3200 Alpine Road
Portola Valley, CA 94028

 

97,840

 

30,532,495

 

16,379,412

 

4,897,841

 

 

 

 

 

 

 

 

 

 

 

Three Arch Associates IV, L.P.

Attention: Bill Harrington
3200 Alpine Road
Portola Valley, CA 94028

 

2,160

 

674,161

 

361,659

 

108,145

 

 

 

 

 

 

 

 

 

 

 

Mayo Foundation for Medical Education and Research

Attn: Jeffrey Torborg
200 1
st Street SW
Rochester, MN 55905

 

1,000,000

 

2,747,252

 

 

 

 



 

Name/Address:

 

No. of Shares
of
Common
Stock

 

No. of Shares of
Series A
Preferred Stock

 

No. of Shares of
Series B
Preferred Stock

 

No. of Shares of
Series C
Preferred Stock

 

Mayo Clinic

Attn: Jeffrey Torborg
200 1
st Street SW
Rochester, MN 55905

 

 

2,747,252

 

1,116,071

 

621,875

 

 

 

 

 

 

 

 

 

 

 

MPM BioVentures IV GmBH & Co. Beteiligungs KG

c/o MPM Capital
The John Hancock Tower
200 Clarendon Street, 54
th Floor
Boston, MA 02116

 

 

346,711

 

185,995

 

62,389

 

 

 

 

 

 

 

 

 

 

 

MPM BioVentures IV-QP, L.P.

c/o MPM Capital
The John Hancock Tower
200 Clarendon Street, 54
th Floor
Boston, MA 02116

 

 

8,999,431

 

4,827,821

 

1,619,423

 

 

 

 

 

 

 

 

 

 

 

MPM Asset Management Investors BV4 LLC

c/o MPM Capital
The John Hancock Tower
200 Clarendon Street, 54
th Floor
Boston, MA 02116

 

 

255,904

 

137,282

 

46,049

 

 

 

 

 

 

 

 

 

 

 

Konstantinos Alataris

411 Acacia Avenue
Palo Alto, CA 94306

 

12,151,745*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael Masterson

750 Battery Street
Suite 400
San Francisco, CA 94111

 

70,939

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Aberdare Ventures III, L.P.

Attention: Paul Klingenstein
Aberdare Ventures
One Embarcadero Center
Suite 4000
San Francisco, CA 94111

 

 

26,972,070

 

10,904,468

 

 

 

 

 

 

 

 

 

 

 

 

Aberdare Partners III, L.P.

Attention: Paul Klingenstein
Aberdare Ventures
One Embarcadero Center
Suite 4000
San Francisco, CA 94111

 

 

633,817

 

256,246

 

 

 



 

Name/Address:

 

No. of Shares
of
Common
Stock

 

No. of Shares of
Series A
Preferred Stock

 

No. of Shares of
Series B
Preferred Stock

 

No. of Shares of
Series C
Preferred Stock

 

AMV Partners II, L.P.

Attention: Gordon Wyatt
AMV Partners II LP
2905 Premiere Parkway,
Suite 150
Duluth, GA 30097

 

 

24,005,120

 

12,877,747

 

3,565,327

 

 

 

 

 

 

 

 

 

 

 

Mark B. Knudson

c/o EnteroMedics
2800 Patton Road

St. Paul, MN 55113

 

 

206,043

 

 

17,029

 

 

 

 

 

 

 

 

 

 

 

Mark B. Knudson Revocable Trust

Mark B. Knudson, Trustee
Dorsey & Whitney Trust
Company, LLC, Trustee
c/o EnteroMedics
2800 Patton Road
St. Paul, MN 55113

 

400,000

 

139,389

 

 

11,520

 

 

 

 

 

 

 

 

 

 

 

Susan J. Knudson Revocable Trust

Susan J. Knudson, -Trustee
Dorsey & Whitney Trust
Company, LLC, Trustee
c/o EnteroMedics
2800 Patton Road
St. Paul, MN 55113

 

 

138,325

 

 

11,433

 

 

 

 

 

 

 

 

 

 

 

Sarah Brenzel Conrad

12557 Riverview Road
Eden Prairie, MN 55347

 

290,000

 

144,972

 

61,988

 

17,105

 

 

 

 

 

 

 

 

 

 

 

Adrianus P. Donders

15089 Crane Street
Andover, MN 55304

 

250,000

 

139,389

 

 

 

 

 

 

 

 

 

 

 

 

 

Robert S. Nickoloff

 

100,000

 

69,644

 

 

5,756

 

 

 

 

 

 

 

 

 

 

 

James R. Thacker and Kate Ward Thacker

4529 Thunder Ridge
Eureka, MO 63025

 

141,872

 

549,450

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael DeMane

c/o Nevro Corp.
4040 Campbell Avenue #210
Menlo Park, California 94025

 

13,403,954

 

 

 

 

 



 

Name/Address:

 

No. of Shares
of
Common
Stock

 

No. of Shares of
Series A
Preferred Stock

 

No. of Shares of
Series B
Preferred Stock

 

No. of Shares of
Series C
Preferred Stock

 

 

 

 

 

 

 

 

 

 

 

Andrew Galligan

c/o Nevro Corp.
4040 Campbell Avenue #210
Menlo Park, California 94025

 

3,639,843**

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Andre Walker

c/o Nevro Corp.
4040 Campbell Avenue #210
Menlo Park, California 94025

 

4,136,186**

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NEA Ventures 2013, Limited Partnership

1954 Greenspring Drive
Suite 600
Timonium, MD 21093

 

 

 

 

53,996

 

 

 

 

 

 

 

 

 

 

 

New Enterprise Associates 14, L.P.

1954 Greenspring Drive
Suite 600
Timonium, MD 21093

 

 

 

 

30,183,584

 

 

 

 

 

 

 

 

 

 

 

Covidien Group S.a.r.l.

3b, bd Prince Henri
Luxembourg, L-1724
Luxembourg

 

 

 

 

4,319,654

 

 


*  Includes options to purchase 10,926,742 shares of Common Stock

 

**   Options to purchase Common Stock